Publications by authors named "John Crison"

Claim this Profile
U
Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.
Christoph Gesenberg, Neil R Mathias, Yan Xu, John Crison, Ishani Savant

Pharm Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling.
Shruthi Vaidhyanathan, Xiaoning Wang, John Crison, Sailesh Varia, Julia Z H Gao

J Pharm Sci· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid.
Paul A Dickinson, Filippos Kesisoglou, Talia Flanagan, Marilyn N Martinez, Hitesh B Mistry, John R Crison

J Pharm Sci· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
David J Good, Ruiling Hartley, Neil Mathias, John Crison, Giridhar Tirucherai

Mol Pharm· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug.
Ajit S Narang, Sherif Badawy, Qingmei Ye, Dhaval Patel, Maria Vincent, John Crison

Pharm Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models.
Neil Mathias, Yan Xu, Balvinder Vig, Umesh Kestur, Amy Saari, John Crison

AAPS J· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.
Arzu Selen, Paul A Dickinson, Anette Müllertz, John R Crison, Hitesh B Mistry

J Pharm Sci· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From bench to humans: formulation development of a poorly water soluble drug to mitigate food effect.
Preetanshu Pandey, Rhye Hamey, Dilbir S Bindra, Zongyun Huang, Neil Mathias, John Crison

AAPS PharmSciTech· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-by-design: are we there yet?
Jack Cook, Maria T Cruañes, Manish Gupta, Steve Riley, John Crison

AAPS PharmSciTech· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy.
Neil R Mathias, Yan Xu, Dhaval Patel, Michael Grass, Brett Caldwell, John Crison

Mol Pharm· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic insights into the scale-up of the roller compaction process: a practical and dimensionless approach.
Jasmine M Rowe, John R Crison, Thomas J Carragher, Nipa Vatsaraj, Ryan J McCann

J Pharm Sci· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of modeling tools to drive efficient oral product design.
Neil R Mathias, John Crison

AAPS J· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling.
Jonathan Brown, John Crison, Peter Timmins

Ther Deliv· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling.
John R Crison, Peter Timmins, Anther Keung, Vijay V Upreti, David W Boulton

J Pharm Sci· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive models for drugs exhibiting negative food effects based on their biopharmaceutical characteristics.
Venugopal P Marasanapalle, John R Crison, Krishna R Devarakonda, Xiaoling Li, Bhaskara R Jasti

Drug Dev Ind Pharm· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the effect of fed-state intestinal contents on drug dissolution.
Ece Dilber Gamsiz, Mukul Ashtikar, John Crison, Walt Woltosz, Michael B Bolger

Pharm Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit.
Arzu Selen, Maria T Cruañes, Anette Müllertz, Paul A Dickinson, Jack A Cook, John Crison

AAPS J· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of some factors contributing to negative food effects.
Venugopal P Marasanapalle, John R Crison, Jingwen Ma, Xiaoling Li, Bhaskara R Jasti

Biopharm Drug Dispos· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis